Home/Filings/4/0001209191-21-051015
4//SEC Filing

Atlas Venture Associates X, LLC 4

Accession 0001209191-21-051015

CIK 0001815442other

Filed

Aug 11, 8:00 PM ET

Accepted

Aug 12, 10:42 AM ET

Size

8.6 KB

Accession

0001209191-21-051015

Insider Transaction Report

Form 4
Period: 2021-08-11
Transactions
  • Sale

    Common Stock

    2021-08-11$61.00/sh242,133$14,770,1130 total
Holdings
  • Common Stock

    (indirect: See footnote)
    5,763,012
Footnotes (3)
  • [F1]The shares reported herein give effect to the pro rata distribution of shares by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"), on May 18, 2021, for no additional consideration to its limited partners and its general partner, Atlas Venture Associates X, L.P. ("AVA X LP"), subsequent to the Reporting Persons' last Section 16 filing reporting ownership of the Issuer's Common Stock. As the distribution of such shares constituted only a change in the form of the Reporting Persons' ownership in such shares, the Reporting Persons were not required to report the distribution pursuant to Section 16.
  • [F2]The shares are held directly by AVA X LP. Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. AVA X LLC disclaims Section 16 beneficial ownership of the securities held by AVA X LP except to the extent of its pecuniary interest therein, if any.
  • [F3]These shares are held directly by Atlas Venture Fund X. The general partner of Atlas Venture Fund X is AVA X LP and the general partner of AVA X LP is AVA X LLC. Each of AVA X LP and AVA LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of its respective pecuniary interest therein, if any.

Issuer

Kymera Therapeutics, Inc.

CIK 0001815442

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001742765

Filing Metadata

Form type
4
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 10:42 AM ET
Size
8.6 KB